The combination of CDK4/6 inhibitors and endocrine therapy have been shown to improve clinical outcome in patients with ER+ metastatic BC [11–13], and have since become approved as 1st and 2nd line treatment options. This evidence concerns the gene CDK4 and breast cancer.